JP2019506167A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019506167A5 JP2019506167A5 JP2018539984A JP2018539984A JP2019506167A5 JP 2019506167 A5 JP2019506167 A5 JP 2019506167A5 JP 2018539984 A JP2018539984 A JP 2018539984A JP 2018539984 A JP2018539984 A JP 2018539984A JP 2019506167 A5 JP2019506167 A5 JP 2019506167A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid residues
- modified forms
- proteinaceous molecule
- basic amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000539 amino acid group Chemical group 0.000 claims 22
- 239000003814 drug Substances 0.000 claims 19
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 102000001892 Protein Kinase C-theta Human genes 0.000 claims 2
- 108010015499 Protein Kinase C-theta Proteins 0.000 claims 2
- 230000002209 hydrophobic effect Effects 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 210000000130 stem cell Anatomy 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000007705 epithelial mesenchymal transition Effects 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 230000007498 myristoylation Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 230000001681 protective effect Effects 0.000 claims 1
- 230000007704 transition Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021178010A JP2022023949A (ja) | 2016-02-01 | 2021-10-29 | タンパク質性化合物とその利用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2016900314A AU2016900314A0 (en) | 2016-02-01 | Proteinaceous compounds and uses therefor | |
| AU2016900314 | 2016-02-01 | ||
| PCT/AU2017/050083 WO2017132728A1 (en) | 2016-02-01 | 2017-02-01 | Proteinaceous compounds and uses therefor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021178010A Division JP2022023949A (ja) | 2016-02-01 | 2021-10-29 | タンパク質性化合物とその利用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019506167A JP2019506167A (ja) | 2019-03-07 |
| JP2019506167A5 true JP2019506167A5 (OSRAM) | 2021-02-25 |
| JP7341451B2 JP7341451B2 (ja) | 2023-09-11 |
Family
ID=59499146
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018539984A Active JP7341451B2 (ja) | 2016-02-01 | 2017-02-01 | タンパク質性化合物とその利用 |
| JP2021178010A Pending JP2022023949A (ja) | 2016-02-01 | 2021-10-29 | タンパク質性化合物とその利用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021178010A Pending JP2022023949A (ja) | 2016-02-01 | 2021-10-29 | タンパク質性化合物とその利用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10487115B2 (OSRAM) |
| EP (1) | EP3411061A4 (OSRAM) |
| JP (2) | JP7341451B2 (OSRAM) |
| CN (2) | CN116082457A (OSRAM) |
| AU (1) | AU2017214761B2 (OSRAM) |
| CA (1) | CA3011870A1 (OSRAM) |
| SG (1) | SG11201806122YA (OSRAM) |
| WO (1) | WO2017132728A1 (OSRAM) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111587120A (zh) * | 2017-11-08 | 2020-08-25 | 艾比克斯治疗私人有限公司 | 免疫原性组合物及其用途 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US5976567A (en) | 1995-06-07 | 1999-11-02 | Inex Pharmaceuticals Corp. | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| KR19990082463A (ko) | 1996-02-13 | 1999-11-25 | 돈 리사 로얄 | 혈관 내피 성장 인자 억제제로서의 퀴나졸린유도체 |
| AU719327B2 (en) | 1996-03-05 | 2000-05-04 | Astrazeneca Ab | 4-anilinoquinazoline derivatives |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| AUPP807899A0 (en) | 1999-01-08 | 1999-02-04 | University Of Queensland, The | Codon utilization |
| CA2296067C (en) | 1997-07-09 | 2008-10-07 | The University Of Queensland | Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue |
| AU2481800A (en) * | 1998-12-17 | 2000-07-03 | La Jolla Institute For Allergy And Immunology | Pkc-interacting cousin of trx (picot) polypeptides, polynucleotides, and methodsof making and using them |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| EP1289952A1 (en) | 2000-05-31 | 2003-03-12 | AstraZeneca AB | Indole derivatives with vascular damaging activity |
| MXPA02012905A (es) | 2000-07-07 | 2004-07-30 | Angiogene Pharm Ltd | Derivados de colquinol como agentes de dano vascular.. |
| WO2002008213A1 (en) | 2000-07-07 | 2002-01-31 | Angiogene Pharmaceuticals Limited | Colchinol derivatives as angiogenesis inhibitors |
| AU2000265054A1 (en) | 2000-07-31 | 2002-02-13 | Dabur Research Foundation | Lipid-peptide conjugates for treatment of cancer |
| EP1515964A1 (en) | 2002-06-14 | 2005-03-23 | ALTANA Pharma AG | Substituted diaminopyrimidines |
| US20070072281A1 (en) * | 2003-02-28 | 2007-03-29 | Gabriele Rummel | Three-dimensional structure of the catalytic domain of protein kinase c theta, methods and uses thereof |
| CA2604243C (en) | 2004-04-14 | 2015-11-24 | Avirid, Inc. | Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases |
| EP1991560B1 (en) | 2006-02-20 | 2018-04-04 | Ewha University-Industry Collaboration Foundation | Peptide having cell membrane penetrating activity |
| DK2635596T3 (da) * | 2010-11-01 | 2019-11-25 | Univ Sydney Technology | Immun-moduleringsmidler og anvendelser dertil |
| HRP20181175T1 (hr) * | 2011-03-11 | 2018-09-21 | Vib Vzw | Molekule i postupci za inhibiciju i otkrivanje proteina |
| JP6550333B2 (ja) | 2012-09-27 | 2019-07-24 | ザ ユニヴァーシティ オヴ ブリティッシュ コロンビア | ペプチドに誘導されたタンパク質ノックダウン |
| WO2015039187A1 (en) * | 2013-09-18 | 2015-03-26 | University Of Canberra | Stem cell modulation ii |
| EP3185858A4 (en) * | 2014-08-25 | 2017-12-27 | University of Canberra | Compositions for modulating cancer stem cells and uses therefor |
-
2017
- 2017-02-01 CA CA3011870A patent/CA3011870A1/en not_active Abandoned
- 2017-02-01 WO PCT/AU2017/050083 patent/WO2017132728A1/en not_active Ceased
- 2017-02-01 CN CN202211550292.7A patent/CN116082457A/zh active Pending
- 2017-02-01 AU AU2017214761A patent/AU2017214761B2/en active Active
- 2017-02-01 EP EP17746642.2A patent/EP3411061A4/en active Pending
- 2017-02-01 US US16/074,690 patent/US10487115B2/en active Active
- 2017-02-01 CN CN201780021694.9A patent/CN108883155A/zh active Pending
- 2017-02-01 SG SG11201806122YA patent/SG11201806122YA/en unknown
- 2017-02-01 JP JP2018539984A patent/JP7341451B2/ja active Active
-
2021
- 2021-10-29 JP JP2021178010A patent/JP2022023949A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110114075B (zh) | 含有二硫化物的细胞穿透肽及其制备和使用方法 | |
| EP2594582A3 (en) | Peptide vaccines with Seq Id No: 110, 111, 387, 112, 394 114, 116, 117 or 121 for cancers expressing tumor-associated antigens | |
| JP2019512478A5 (OSRAM) | ||
| US20240368224A1 (en) | Bicyclic peptidyl pan-ras inhibitors | |
| JP2002502376A (ja) | 生物学的膜を横切る輸送を増強するための組成物および方法 | |
| JP2013172743A5 (OSRAM) | ||
| ES2640814T3 (es) | Inhibidores selectivos de caspasa y usos de los mismos | |
| MX2009010965A (es) | Péptidos de tem8 y vacunas que los contienen. | |
| SA515360970B1 (ar) | تركيب صيدلي يشتمل على إنزيم دي إميناز آرجينين رابط للألبومين يستهدف علاج السرطان | |
| WO2015067712A1 (en) | Immunosuppressive agents and their use in therapy | |
| JP2006506942A5 (OSRAM) | ||
| JP2019534317A5 (OSRAM) | ||
| SG10201407944TA (en) | Imp-3 oligopeptides and vaccines including the same | |
| US20120122799A1 (en) | Cyclic peptide antitumor agents | |
| CA3080617A1 (en) | Polypeptide conjugates for intracellular delivery of stapled peptides | |
| CA3087761A1 (en) | Proteinaceous molecules and uses therefor | |
| CN104968673A (zh) | 融合多肽及使用方法 | |
| US9364514B2 (en) | Anti-tumor adjuvant therapy | |
| JP2019505210A5 (OSRAM) | ||
| JP2019506167A5 (OSRAM) | ||
| RU2018126487A (ru) | Противораковые вакцины | |
| KR20180086277A (ko) | 폴리펩티드 화합물, 그리고 이의 제조 방법 및 적용 | |
| JP2017525357A5 (OSRAM) | ||
| CN104130311B (zh) | 一种抗肿瘤肽变体及其应用 | |
| US7750114B2 (en) | Peptides having a high cysteine content |